Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06623110 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

Study acronym: INTERCEPT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jan 1, 2026 to Jan 1, 2027
    • Study completion date: Jan 1, 2028 to Jan 1, 2029
    • Start date changed from estimate of Mar 2025 to Jan 1, 2025
    • Site details revised at 2 of 2 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Glenn J. Hanna
3 trials monitored
See 1 trial at risk
The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live Herpes Simplex V-1 strain)
Trial Details
NCT Number NCT06623110
Lead Sponsor Glenn J. Hanna
Collaborators: Replimune, Inc.
Conditions
(from sponsor)		 High-Risk Oral Precancerous Disease
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov